Yiannis Koullias, MD

Gilead Sciences, Inc.

Disclosure(s): Gilead Sciences, Inc.: Employee, Stocks/Bonds (Public Company)

Poster(s):

• (P-1231) A Phase 1 Open-label, Parallel-group, Single-dose Study to Evaluate the Pharmacokinetics and Safety of Obeldesivir in Participants with Normal Renal Function and Renal Impairment
  Tuesday, October 21, 2025

  12:15 PM - 1:30 PM US ET

• (P-1625) SARS-CoV-2 Viral Load Dynamics in Participants With Solid Organ Transplantation and Severely Reduced Kidney Function From the Remdesivir Phase 3 REDPINE Study Who Were Hospitalized for COVID-19
  Wednesday, October 22, 2025

  12:15 PM - 1:30 PM US ET